Carl L. Gordon - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 3, 2026
Carl L. Gordon has filed 2 SEC Form 4 filings across 1 company in the last 90 days - active on both sides. Lifetime open-market purchases: $15.00M. Lifetime open-market sales: $5.68M.
Profile
Carl L. Gordon serves as Director of Compass Therapeutics, Inc. (CMPX). Gordon has also held reporting roles at Keros Therapeutics, Inc. (KROS) and Lomond Therapeutics Holdings, Inc.. Gordon has reported 7 insider filings with the SEC since 2024. The most recent filing was in January 2026.
| Role | Director |
|---|---|
| Notability | 36/100 |
Board memberships
- Compass Therapeutics, Inc.
- Keros Therapeutics, Inc.
- Lomond Therapeutics Holdings, Inc.
Reported roles
- Director
- Director
- Director
Trading Pattern
InsiderAlpha's records for Carl L. Gordon go back to 2024: 7 primary Form 4 filings, an average of 2.3 per year. The typical open-market purchase is $15.00M (1 buy totaling $15.00M). The largest single buy on record is $15.00M of SCTX in 2026. Sales side: 1 recorded sale totaling $5.68M, so the filing history runs buy-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Carl L. Gordon has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at Scribe Therapeutics, Inc. (SCTX) - 2 filings, 2026
- Director at Compass Therapeutics, Inc. (CMPX) - 1 filing, 2026
- Director at Keros Therapeutics, Inc. (KROS) - 1 filing, 2025
- Insider at Keros Therapeutics, Inc. (KROS) - 1 filing, 2025
- Director, 10% Owner at Compass Therapeutics, Inc. (CMPX) - 1 filing, 2025
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-29 | SCTX | Scribe Therapeutics, Inc. | P - Open-market purchase | 1.00M | $15.00 | $15.00M |
| 2026-07-29 | SCTX | Scribe Therapeutics, Inc. | J - Other acquisition / disposition | 348.8K | - | |
| 2025-12-18 | KROS | Keros Therapeutics, Inc. | D - Derivative transaction | 74.5K | $17.75 | $1.32M |
| 2025-12-18 | KROS | Keros Therapeutics, Inc. | D - Derivative transaction | 140.1K | $17.75 | $2.49M |
| 2025-06-04 | KROS | Keros Therapeutics, Inc. | A - Grant or award | 5.2K | $0.00 | |
| 2025-04-09 | CMPX | Compass Therapeutics, Inc. | S - Open-market sale | 3.57M | $1.59 | $5.68M |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | A - Grant or award | 155.1K | $4.00 | $620K |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | A - Grant or award | 479.7K | $4.00 | $1.92M |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | A - Grant or award | 808.9K | $4.00 | $3.24M |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | J - Other acquisition / disposition | 74.6K | $3.60 | $269K |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | J - Other acquisition / disposition | 230.8K | $3.60 | $831K |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | J - Other acquisition / disposition | 389.1K | $3.60 | $1.40M |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | J - Other acquisition / disposition | 215.1K | $3.20 | $688K |
| 2024-11-05 | - | Lomond Therapeutics Holdings, Inc. | J - Other acquisition / disposition | 323.9K | $3.20 | $1.04M |
Companies - Last 90 Days
- Scribe Therapeutics, Inc. (SCTX) - 2 filings, last 2026-07-29
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Carl L. Gordon has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Behzad Aghazadeh - $36.26M of SCTX open-market activity in the last 12 months
- ORBIMED ADVISORS LLC - $15.00M of SCTX open-market activity in the last 12 months
- AH Bio Fund II, L.P. - $5.00M of SCTX open-market activity in the last 12 months
- Svetlana Lucas - $45K of SCTX open-market activity in the last 12 months
- David Parrot - $40K of SCTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Sabas D. Carrillo
- Jonathan P. Carroll
- CASCADE INVESTMENT, L.L.C.
- Casdin Capital, LLC
- Casdin Partners Master Fund, L.P.
- Richard M. Cashin Jr.
- Catalyst4, Inc.
- CDR Channel Holdings II, L.P.
Frequently Asked Questions
Who is Carl L. Gordon?
Carl L. Gordon serves as Director of Compass Therapeutics, Inc. (CMPX). Gordon has also held reporting roles at Keros Therapeutics, Inc. (KROS) and Lomond Therapeutics Holdings, Inc.. Gordon has reported 7 insider filings with the SEC since 2024. The most recent filing was in January 2026.…
How many SEC Form 4 filings has Carl L. Gordon submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Carl L. Gordon been buying or selling stock?
Recorded transactions: 1 open-market purchase ($15.00M) and 1 open-market sale ($5.68M) across all tracked filings.
Where can I see all of Carl L. Gordon's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Carl L. Gordon profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.